Menu Search
Equities

AIM Vaccine Co Ltd

6660:HKG.HS

AIM Vaccine Co Ltd

Actions
  • Price (HKD)7.38
  • Today's Change-0.10 / -1.34%
  • Shares traded235.20k
  • 1 Year change-83.15%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)1.28bn
  • Net income in HKD-1.40bn
  • Incorporated2011
  • Employees1.62k
  • Location
    AIM Vaccine Co Ltd25/FBuilding A, 91 Jianguo Road, ChaoyangBEIJING 110000ChinaCHN
  • Phone+86 1 085950621
  • Websitehttps://www.aimbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.